Ormeloxifene-A new treatment modality in Dysfunctional Uterine Bleeding: efficacy and safety

Karmakar, Sanchita; Deshpande, Hemant

doi:10.5958/2394-2754.2016.00051.5

Cited by 2 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were also explained by Dasgupta, M, et al,2016, in West Bengal Amenorrhea caused by both the drugs was counted as side effect rather we found it welcome by the patient to recover their anaemia and mental distress that was caused by HMB.The side effect profile included no major event, similar to the study conducted by Carbonell Esteve et al,2008 Cuba and Sachita Karmakar et al,2013 in Pune 27,28 Conclusion Treatment of uterine fibroids by mifepristone or ormeloxifen was associated with reduction in menstrual blood loss and pain with equal efficacy. It was found that mifepristone reduced the size of fibroid more effectively while ormeloxifen had significant effect on endometrial thickness.…”

Section: Resultssupporting

confidence: 89%

Comparison of ormeloxifen and mifepristone in management of leiomyoma uterus

Singh¹,

Chourasia²,

Singh³

et al. 2021

IJOGR

View full text Add to dashboard Cite

Aims and Objectives: To compare the effect of mifepristone and ormeloxifen on symptomatology, size and vascularity of fibroid and also to compare the compliance and side effects of both these drugs. Materials and Methods: This study was conducted in the department of obstetrics and gynecology at Swaroop Rani Nehru hospital, Allahabad and Kamla Nehru memorial hospital, Allahabad over a period of one year between 2016-2017 in 90 fibroid patients who gave consent for the study. Depending on their choice they were randomly divided into 2 groups. Group A included 44 fibroid patients who were given mifepristone and Group B included 46 fibroid patients were given ormeloxifen. Assessment of heavy menstrual bleeding by pictorial blood loss assessment chart, dysmenorrhea and dyspareunia by visual analogue scale, estimation of hemoglobin and repeat imaging to assess size, number, endometrial thickness, Doppler velocimetry of fibroid was done and all variables were compared in relation to pretreatment and post-treatment parameters by using chi square test. Results: 97.7% patients in group A and 95.6% patients in group B were compliant towards treatment. A significant reduction in HMB (group A-51.16% to 18.6% $ group B-45.45% to 20.45%),mean pbac score(group A-246.6 to 65.2;p<0.

show abstract

Section: Resultssupporting

confidence: 89%

Comparison of ormeloxifen and mifepristone in management of leiomyoma uterus

Singh¹,

Chourasia²,

Singh³

et al. 2021

IJOGR

View full text Add to dashboard Cite

show abstract

“…Chawla et al [2], in their 2017 study, showed that use of centchroman (ORM) in conservative management of menorrhagia in premenopausal age group resulted in an increase of Hb level at the end of the study. Karmakar and Deshpande [3], in 2016, had done a study of efficacy and safety of ORM in a new treatment for DUB and the result was similar to our study. Jacob and Mini, [4] in their study in 2015, did a comparative study of both the drugs.…”

Section: Vardaini Et Alsupporting

confidence: 88%

“…They have varied tissue response which behaves as an estrogen antagonist in uterus and breast, being mildly agonist action on vagina, bone mineral density, central nervous system, and serum lipids, making it the perfect SERM for AUB-O. The current study was undertaken to the hypothesis that ormeloxifene (ORM) is superior to cyclical progesterone therapy in the treatment of pre-menopausal AUB-O [3].…”

Section: Introductionmentioning

confidence: 99%

Comparison of Efficacy and Safety of Ormeloxifene and Cyclical Progesterone (Norethisterone) in Ovulatory Abnormal Uterine Bleeding

Vardaini¹,

Mishra

Ranjan

et al. 2020

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective-To determine the efficacy and safety of ormeloxifene versus progesterone in controlling Ovulatory Abnormal Uterine Bleeding(AUB-O) Methods-A Prospective Randomized comparative study of total 100 females of reproductive age group 25 to 45 years with AUB-O.Patients were randomly divided in two groups of 50 each. Results-The study showed ormeloxifene was found to be more effective and safe than Norethisterone in AUB-O. Ormeloxifine as compared to norethisterone is more effective in improving Hb and reducing endometrial thickness. Hence, ORM is more superior than Norethisterone Conclusion-In this study ormeloxifene was found to be more effective in reducing blood loss,that leads to improvement in mean haemoglobin and also it had more ability to reduce endometrial thickness.As both ormeloxifene and norethisterone are very effectivebut ormeloxifene is safe , cost effective ,nonsteroidal, non hormonal drug with convenient dosage and better compliance for medical management of AUB-O.Hence, ormeloxifene canbe considered as first drugs in the management of AUB-O.

show abstract

Ormeloxifene-A new treatment modality in Dysfunctional Uterine Bleeding: efficacy and safety

Cited by 2 publications

References 2 publications

Comparison of ormeloxifen and mifepristone in management of leiomyoma uterus

Comparison of ormeloxifen and mifepristone in management of leiomyoma uterus

Comparison of Efficacy and Safety of Ormeloxifene and Cyclical Progesterone (Norethisterone) in Ovulatory Abnormal Uterine Bleeding

Contact Info

Product

Resources

About